1 percent metformin Gel Improves Healing in Periodontal Disease When Used with Conventional Therapy: Study

The authors systematically analyzed six clinical trials comparing SRP plus 1% MF gel to SRP with placebo in patients with periodontitis. Follow-up was conducted at three and six months. Results showed a consistent, statistically significant improvement in key clinical parameters with the metformin gel. Pocket depth (PD) reduction averaged 1.33 mm at three months (95% CI: −1.66 to −1.01) and 1.87 mm at six months (95% CI: −2.24 to −1.39). Clinical attachment level (CAL) gain was 1.80 mm (95% CI: −2.26 to −1.34) at three months and 2.14 mm (95% CI: −2.71 to −1.58) at six months. Intra-bony defect (IBD) depth also improved by 1.16 mm (95% CI: −1.40 to −0.92) at six months. These substantial improvements suggest that metformin’s local anti-inflammatory and osteogenic properties meaningfully support periodontal healing. The authors concluded that 1% MF gel, when used adjunctively, enhances the healing process in periodontal disease beyond the effects of SRP alone. They recommend the incorporation of this gel into clinical practice for improved management of periodontitis, especially in cases resistant to traditional treatment. As a first-line antidiabetic agent, metformin’s repurposed use in periodontics—a field where inflammation and bone loss are central—holds exciting promise for broader host-modulation strategies in oral health.